

12th AHOS 2025

AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM

25-28 SEPTEMBER 2025

Antalya, Turkey | Royal Seginus Hotel



25 SEPTEMBER 2025, THURSDAY

15:30-16:00	Registrations – Coffee
16:00-16:30	AHOS 2025-Opening remarks
	Summary of the previous AHOS: 2014-2024 Güray Saydam, TR – Evangelos Terpos, GR
16:30-18.00	SESSION 1: MYELODYSPLASTIC SYNDROMES
Moderators:	Mustafa Çetiner, TR – Ioannis Kotsianidis, GR
Lecture: Speaker:	Age-Related Diseases in MDS Konstantinos Liapis, GR
Lecture: Speaker:	Treatment of High-Risk MDS Meltem Kurt Yüksel, TR
Lecture: Speaker:	Myelodysplastic Syndrome with <i>TP53</i> Mutations Vassiliki Papa, GR
18:00-18:30	Coffee Break
18:30-19.00	Meet the Expert 1: Management of anemia in low risk MDS
Moderator: Speaker:	İrfan Yavaşoğlu , TR Ümit Yavuz Malkan, TR
19:00-19.30	Satellite Lecture (sponsored by AOP): Clinical & Molecular Responses of Patients with Low Risk PV: the Role of RopegIFN
Moderator: Speaker:	Sotirios Papageorgiou, GR Evangelos Terpos, GR
19:30-20.00	Meet the Expert 2: CALR Mutations in Myeloproliferative Neoplasms Pathogenesis and Treatment
Moderator: Speaker:	Panayiotis Panayiotidis, GR Stavroula Giannouli, GR
21:00	Opening Ceremony - Welcome Reception

26 SEPTEMBER 2025, FRIDAY

09:00-10:00	SESSION 2: ACUTE LYMPHOBLASTIC LEUKEMIA
Moderators:	Maria Pagoni, GR - Mahmut Töbü, TR
Lecture:	BİTE/TKI in PH+ ALL
Speaker:	Simge Erdem, TR
Lecture:	CAR-T cell therapy for T-ALL
Speaker:	Ioannis Tsonis, GR
10:00-10:30	Special Topics-1: Multiple Myeloma and Underestimated Power of IMiDs
Moderator:	Güray Saydam, TR
Speaker:	Onur Hakkı Kırkırlar, TR
10:30-11:00	Satellite Lecture (sponsored by Pfizer): Rapid, Deep and Durable Responses with Elrexfio in R/R MM Treatment
Moderator:	Mehmet Ali Özcan, TR
Speaker:	Ömür Gökmen Sevindik, TR
11:00-11:30	Coffee Break
11:30-12:00	Meet the Expert - 3: Coagulation Disorders in Acute Leukemias
Moderator:	Charis Matsouka, GR
Speaker:	Georgia Kaiafa, GR
12:00-13:00	SESSION 3: ACUTE MYELOBLASTIC LEUKEMIA
Moderators:	Flora Kontopidou, GR – Mehmet Yılmaz, TR
Lecture:	Treatment of elderly patients with AML in 2025
Speaker:	İtir Şirinoğlu Demiriz , TR
Lecture:	Overcoming Therapy Resistance in AML
Speaker:	Panagiotis Tsirigotis, GR
13:00-13:30	Meet the Expert - 4: How I treat Hemophagocytic Syndrome?
Moderator:	Despina Mparmparoussi (GR)
Speaker:	Marie-Christine Kyrtsonis, GR

13:30-14:30	Lunch Break
14:30-15:10	Poster Session 1 - Poster View and Discussion (P1 – P17)
Moderators:	Utku İltar, TR–Ufuk Demirci, TR–Anastasia Pouli, GR–Neslihan Mandacı Şanlı, TR
15:10-16:30	Oral Session 1
Moderators:	Pelin Aytan, TR – Nikolaos Giannakoulas, GR
15:10-15:20	O1- Comparison of Transplant Outcomes with Non-cryopreserved Hematopoietic Stem Cell Transplantation versus Conventional Autologous Peripheral Stem Cell Transplantation; Results of a Single-Center Experience Presenter: Ramazan Öcal
15:20-15:30	O2- Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapies Presenter: Foteini Theodorakakou
15:30-15:40	O4- Retrospective Analysis of Primary Hypereosinophilia Cases: Preliminary Findings from Next-Generation Sequencing Presenter: Zehra Akşit Bozkına
15:40-15:50	O9- Novel criteria for evaluating early treatment response with whole body magnetic resonance imaging and prognostic implications in patients with newly diagnosed multiple myeloma and focal lesions Presenter: Ioannis Ntanas-Stathopoulos
15:50-16:00	O5- Targeting STAT5A via CRISPR/Cas9 Restores TKI Sensitivity in Resistant Chronic Myeloid Leukemia Cells Presenter: Besne Celik
16:00-16:10	O13- Updated results of sonrotoclax + dexamethasone, an all-oral treatment, in patients with t(11;14)-positive relapsed/refractory multiple myeloma Presenter: Maria Gavriatopoulou
16:10-16:20	O6- Blastic Plasmacytoid Dendritic Cell Neoplasia: Single Center Results with Conventional Treatment Options Presenter: Denis Çetin
16:20-16:30	O23- Deletion 17P, And Igh High Risk Translocations Along With Chromosome 1 Abnormalities Are The Strongest Survival Predictors In Multiple Myeloma: A Real-World Validation By The Greek Myeloma Study Group Presenter: Eirini Katodritou
16:30-18:00	SESSION 4: NON-HODGKIN'S LYMPHOMA
Moderators:	Burhan Ferhanoğlu, TR – Evangelos Terpos, GR
Lecture:	How I Treat Splenic Lymphoma?

12TH AHOS – 25-28 OF SEPTEMBER 2025 – ANTALYA, TURKEY

Speaker:	Christina Kalpadaki, GR
Lecture:	Treatment of Relapsed/Refractory Mantle-Cell Lymphoma
Speaker:	Fatma Keklik Karadağ, TR
Lecture:	Primary CNS Lymphoma
Speaker:	Maria Bouzani, GR
18:00-18:30	Meet the Expert - 5: How I Treat Double Hit Lymphomas?
Moderators:	Nikos Harhalakis, GR - Özgür Mehtap, TR
Speaker:	Theodoros Vassilakopoulos, GR
18:30-19:00	Coffee Break
19:00-19:30	Meet the Expert - 6: Lenalidomide Treatment for Patients with MDS and del(5)q: Which Patients Should Be Treated, When to Start Treatment, and Which Are the Predictive Factors for a Favorable Response?
Moderators:	Alexandra Kourakli, GR - Asu Fergün Yılmaz, TR
Speaker:	Argiris Symeonidis, GR
19:30-20:00	Satellite Lecture (sponsored by Alexion): PNH and Eculizumab Treatment
Moderator:	Güray Saydam, TR
Speaker:	Asu Fergun Yılmaz, TR

27 SEPTEMBER 2025, SATURDAY

09:00-10:30	Session 5: PLASMA CELL NEOPLASMS
Moderators:	Meletios A. Dimopoulos, GR – Ayşe Tülin Tuğlular, TR , Sevgi Kalayoğlu Beşışık, TR
Lecture:	Second Line Therapy for Multiple Myeloma
Speaker:	Sosana Delimpasi, GR
Lecture:	Management of patients who receive Bispecific Antibodies
Speaker:	Onur Hakkı Kırkırlar, TR
Lecture:	Treatment of Solitary Bone Plasmacytoma
Speaker:	Eirini Katodritou, GR
10:30-11:00	Satellite Lecture (sponsored by Integris): Translating Data of XPO1 Inhibition into Actionable Clinical Profiles and Beyond
Moderator:	Maria Gavriatopoulou, GR
Speaker:	Meletios A. Dimopoulos, GR
11:00-11:30	Coffee Break
11:30-12:30	SESSION 5: Allogeneic Transplantation & Gene Therapy
Moderator:	Ioannis Baltadakis, GR – Filiz Vural, TR
Debate:	Does Cord Blood Provide a stronger GVL effect than MUD?
Speakers:	Yes: Ali Ünal, TR No: Damianos Sotiropoulos, GR
Lecture:	What is the Role of Gene Therapy in Hemophilia
Speaker:	Eleni Gavriilaki, GR
12:30-13:00	Meet the Expert - 7: CAR T Cells: Curative Treatment or Bridging to Transplant in a Selective Patient Group?
Moderator:	Ioannis Batsis (GR)
Speaker:	Christos Demosthenous (GR)

13:00-13:30	Special Topics-2: Thrombocytopenia: Treatment of ITP and Thrombocytopenia in 2025
Moderators:	Fatoş Dilan Köseoğlu, TR - Nur Soyer, TR
Speaker:	Ünal Ataş, TR
13:30-14:40	Lunch Break
14:40-15:40	Poster Session 2 - Poster View and Discussion (P18 – P33)
Moderators:	Ahmet İfran, TR – Ioannis Ntanas-Stathopoulos, GR – Eleni Variami, GR
15:40-17:00	Oral Session 2
Moderators:	Volkan Karakuş, TR – Maria Kotsopoulou, GR
15:40-15:50	O8- Investigation of Potential Antiproliferative Activity of Cannabinoid Type 2 Receptor Ligand in Chronic Myeloid Leukemia Cells Resistant to Tyrosine Kinase Inhibitors Presenter: Hülya Çınar
15:50-16:00	O15- R-da-EPOCH Versus R-Chop-21 In Primary Mediastinal Large B-Cell Lymphoma (PmLbcl): Final Results Of A Real-Life Comparison With Consecutive Historical Controls In Greece Based On 334 Patients Presenter: T.P. Vassilakopoulos
16:00-16:10	O20- Allogeneic Hematopoietic Cell Transplantation Experience in Chronic Lymphocytic Leukemia Cases Presenter: Zehra Akşit Bozkına
16:10-16:20	O17- Treatment Strategies, Outcome and Prognostic Factors of Very Late Relapses in Patients with Hodgkin Lymphoma after Initial Treatment with Chemotherapy ± Radiotherapy: A Hellenic-Italian Joint Study Presenter: T.P. Vassilakopoulos
16:20-16:30	O26- Ten-year single-center experience in patients with immune thrombocytopenia Presenter: Neşe Varlı
16:30-16:40	O18- The Prognostic Significance Of Serum B2- Microglobulin Levels (Sβ2m) In Primary Mediastinal Large B-Cell Lymphoma (PmLbcl) Presenter: T.P. Vassilakopoulos
16:40-16:50	O27- Early-Onset Myelofibrosis with Refractory Iron Deficiency Anemia in a Young Adult with PHOAR2-Enteropathy Syndrome: A Rare Case Presenter: Furkan Durmuş
16:50-17:00	O24- Serum Fas Ligand (sFasL) Levels in patients with WM: Clinical Correlations Presenter: Annita-Ioanna Gkioka

12TH AHOS – 25-28 OF SEPTEMBER 2025 – ANTALYA, TURKEY

17:00-17:30	Meet the Expert - 8: How I treat Transthyretin (ATTR) Amyloidosis?
Moderator:	Zina Vasiliki, GR
Speaker:	Alexandros Briasoulis, GR
17:30-18:00	Coffee Break
18:00-18:30	Special Topics-3: Mast Cell Disorders: From Pathogenesis to Treatment
Moderators:	Anıl Tombak, TR – A. Emre Eşkazan, TR
Speaker:	Eren Arslan Davulcu, TR
18:30-19:15	Invited speaker by the Co-Chairs
Moderators:	Fahri Şahin, TR – Evangelos Terpos, GR
Lecture:	The Journey from Allogeneic Transplantation to Cellular and Gene Therapies
Speaker:	Ioanna Sakellari, GR

28 SEPTEMBER 2025, SUNDAY	
09:00-10:00	Oral Session 3
Moderators:	<p>Ozan Salim, TR – Erdal Kurtoğlu TR</p> <p>O3- Retrospective Comparison of BEAC and BEAM as Conditioning Regimens in Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients: Efficacy and Toxicity Presenter: Berfin Nazlı Torun</p> <p>O14- Burden and characteristics of infections in relapsed/refractory multiple myeloma patients treated with bispecific antibodies and the impact of immunoglobulin replacement Presenter: Eirini Solia</p> <p>O7- Prognostic Significance of the CONUT Score in Hodgkin Lymphoma Presenter: Didem Koca</p> <p>O16- Survival Trends In Hodgkin Lymphoma (HL) From 1980 To 2020: A 40-Year Experience From A Referral Center Presenter: T. Vassilakopoulos</p> <p>O11- Evaluation Of Prognostic Factors In Patients With Peripheral T-Cell Lymphoma Presenter: Tuğba Mermer Aydın</p> <p>O19- Adjusting Serum β2-Microglobulin Levels (sβ2m) According to Renal Function in Diffuse Large B-Cell Lymphoma (DLBCL): Impact on Prognostic Significance Presenter: Theodoros P. Vassilakopoulos</p>
10:00-11:00	Oral Session 4
Moderators:	<p>Ahmet Kürşat Güneş, TR – Orhan Kemal Yücel, TR</p> <p>O12- Single-Center Experience of Selinexor in Combination with Dexamethasone With or Without Bortezomib in Relapsed/Refractory Multiple Myeloma: Preliminary Results Presenter: Zehra Akşit Bozkına</p> <p>O10- Characteristics and clinical course of younger Patients with asymptomatic monoclonal gammopathies: Low risk features and low risk of complications Presenter: Eirini Solia</p> <p>O21- Prognostic Role of Fibrinogen in Patients with Neutropenic Sepsis Presenter: Gülçin Çelebi</p>

12TH AHOS – 25-28 OF SEPTEMBER 2025 – ANTALYA, TURKEY

	O25- Prognostic Significance of Serum Soluble Fas Ligand (sFasL) and Its Association with IL-8 in Multiple Myeloma Presenter: Annita-loanna Gkioka O22- Clinical Spectrum and Prognostic Insights of Systemic Mastocytosis: A Single-Center Experience Presenter: Gülçin Çelebi
11:00-12:30	Scientific Collaboration of AHOS
12:30-13:00	Closing Remarks – AHOS 2026

ORGANIZING COMMITTEE

Co-chairs

Guray Saydam & Evangelos Terpos

Scientific Secretaries

Eirini Katodritou & Fahri Şahin

Members

Türkiye:

Burhan Ferhanoğlu

Ayşe Tülin Tuğlular

Ali Ünal

İrfan Yavaşoğlu

Greece:

Ioannis Adamopoulos

Eleni Chandrinou

Eurydiki Michalis

Christos Poziopoulos

Vasiliki Spiliopoulou

Elissavet Vervesou

SCIENTIFIC COMMITTEE

Co-chairs

Evangelos Terpos & Guray Saydam

Members

Türkiye:

Burhan Ferhanoğlu

Fahri Şahin

Nur Soyer

Mehmet Yılmaz

Greece:

Meletios Athanasios Dimopoulos

Elisavet Grouzi

Ioanna Sakellari

Argiris Symeonidis

Theodoros P. Vassilakopoulos

ABSTRACT REVIEWERS

Türkiye:

Burak Deveci

Fahri Şahin

Ozan Salim

Güray Saydam

Greece:

Panagiotis Diamantopoulos

Nikolaos Giannakoulas

Emmanouel Spanoudakis

Evangelos Terpos